NDATOPICALLOTIONPriority Review
Approved
Dec 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
OXSORALEN (methoxsalen) by Bausch + Lomb is ii. First approved in 1954.
Drug data last refreshed 23h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXSORALEN (methoxsalen) is a photosensitizing psoralen compound administered topically as a lotion for the treatment of Graft Versus Host Disease (GVHD). The drug works by forming covalent bonds with DNA upon UVA (320–400 nm) photoactivation, triggering cell injury and inflammatory repair mechanisms that reduce hyperproliferative disorders.
LOE Approaching
Product is approaching loss of exclusivity with competitive pressure at 30%, indicating downsizing commercial teams and consolidation of brand support roles.
Mechanism of Action
II. CLINICAL PHARMACOLOGY The combination treatment regimen of psoralen (P) and ultraviolet radiation of 320-400 nm wavelength commonly referred to as UVA is known by the acronym, PUVA. Skin reactivity to UVA (320–400 nm) radiation is markedly enhanced by the ingestion of methoxsalen. In a well…
Worked on OXSORALEN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.